Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fluicell ABOSTO:FLUI +4.78%54 3-Year EBITDA Growth Rate is 56.50% as of Mar. 2026, which is 606% above its 10-year median of 8.00. GuruFocus rates OSTO:FLUI with a GF Score™ of 54/100 and a GF Value™ of kr33.47 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,130 Biotechnology companies, Fluicell AB ranks better than 89.03% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 56.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 46.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Fluicell AB was 56.50% per year. The lowest was -44.50% per year. And the median was 8.00% per year.
Fluicell AB (OSTO:FLUI) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Fluicell AB 3-Year EBITDA Growth Rate Related Terms
OSTO:FLUI vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Fluicell AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Fluicell AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 56.50% mean?
Fluicell AB (OSTO:FLUI) has a 3-Year EBITDA Growth Rate of 56.50% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fluicell AB and its competitors. This is 606% above median its historical median of 8.00. According to the industry distribution chart, Fluicell AB ranks #124 out of 1130 companies in the Biotechnology industry, placing it in the top 11%.
Is Fluicell AB's 3-Year EBITDA Growth Rate too high?
Fluicell AB's current 3-Year EBITDA Growth Rate of 56.50% is 606% above median its 10-year median of 8.00. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Fluicell AB's value of 56.50% is 280.5% above this industry median. Based on the distribution chart, Fluicell AB ranks #124 out of 1130 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fluicell AB has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #124 out of 1130 companies for 3-Year EBITDA Growth Rate. This places Fluicell AB in the top 11% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Fluicell AB's value of 56.50% is 280.5% above this benchmark. While the company's 10-year median is 8.00 vs. the industry median of 14.85, Fluicell AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,130 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current 3-Year EBITDA Growth Rate of 56.50% is 280.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Fluicell AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current 3-Year EBITDA Growth Rate is 56.50%, which is 606% above median its own 10-year median of 8.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Fairly Valued. The stock's GF Value™ is kr33.47, compared to a current price of kr32.90 — trading 1.7% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 56.50%, which is 606% above median its 10-year median of 8.00 and 280.5% above the Biotechnology industry median of 14.85. Fluicell AB's overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current 3-Year EBITDA Growth Rate is 56.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued.
The current stock price of kr32.90 is trading 1.7% below its estimated GF Value™ of kr33.47.
GuruFocus considers Fluicell AB to be Fairly Valued.
Key valuation signals for OSTO:FLUI:
3-Year EBITDA Growth Rate: 56.50% (606% above median its 10-year median of 8.00)
GF Value™: kr33.47 vs. price of kr32.90 (1.7% below fair value)
Industry Position: 280.5% above the Biotechnology median (#124 of 1130)
No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
54GF Score
Get the complete analysis for OSTO:FLUI
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:FLUI has been successfully added to your 
